The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO Italy 2020 | Impact of COVID-19 on CLL treatment in Italy
Antonio Cuneo, MD, PhD, University of Ferrara, Ferrara, Italy, outlines the impact of the COVID-19 pandemic on the treatment of chronic lymphocytic leukemia (CLL) in Italy, and outlines the risk of COVID-19 high-risk disease in patients with CLL. Dr Cuneo also discusses the use of the BTK inhibitor ibrutunib, which may show efficacy against the COVID-19 pandemic. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
